NEW YORK, January 3, 2017 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com draws investors' attention back to the Major Drug Manufacturers industry
with the following equities under assessment: Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Sanofi (NYSE: SNY), Biostar
Pharmaceuticals Inc. (NASDAQ: BSPM), and Heron Therapeutics Inc. (NASDAQ: HRTX). These companies belong to the Healthcare sector
which was narrowly mixed on Friday, December 30th, 2016, with the NYSE Health Care Index
climbing about 0.1%, and shares of health care companies in the S&P 500 declining nearly 0.2% as a group. Learn more about
these stocks by downloading their comprehensive and free reports at:
http://stock-callers.com/registration
Immune Pharma
New York headquartered Immune Pharmaceuticals Inc.'s shares finished Friday's session 0.27%
lower at $0.18, with a total trading volume of 2.19 million shares. The stock has gained 9.11% in
the last month. The Company's shares are trading below their 50-day moving average by 6.02%. Moreover, shares of Immune Pharma,
which develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas, have a
Relative Strength Index (RSI) of 46.44.
As per a SEC filing dated December 22nd, 2016, Immune Pharmaceuticals entered into
Amendment No. 1 to the Securities Purchase Agreement (SPA Amendment) on December 16th,
2016, with CrystalClear Group, Inc., (Investor) effective as of December 14th, 2016. The
SPA Amendment amends that certain Securities Purchase Agreement between the Company and the Investor, dated June 30th, 2016. On August 15th, 2016, Immune
Pharmaceuticals entered into two securities purchase agreements with two accredited investors to sell 966,666 shares of its
common stock at a price of $0.36 per share. The Company sold 555,555 shares to the Investor
pursuant to the Securities Purchase Agreement. The SPA Amendment amends the Securities Purchase Agreement to adjust the per share
purchase price paid by the Investor to $0.425 per share. Pursuant to the SPA Amendment, the
Investor will return 84,967 shares to the Company. In consideration of the entering into of the SPA Amendment by the Investor,
Immune Pharmaceuticals has agreed to issue to the Investor a five year warrant to purchase an aggregate of 185,185 shares at an
exercise price of $0.50 per share. IMNP complete research report is just a click away and free
at:
http://stock-callers.com/registration/?symbol=IMNP
Sanofi
Shares in Paris, France headquartered Sanofi ended the day 1.84% higher at $40.44, with a total trading volume of 1.86 million shares. The stock has advanced 0.60% in the last month and
5.89% in the previous three months. The Company's shares are trading 1.91% and 1.42% above their 50-day and 200-day moving
averages, respectively. Moreover, shares of Sanofi, which researches, develops, manufactures, and markets various therapeutic
solutions, have an RSI of 57.02.
On January 02nd, 2017, Sanofi and Boehringer Ingelheim confirmed that the strategic
transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business
(Merial) and Boehringer Ingelheim's consumer healthcare business, has been successfully closed in most markets on January 01st, 2017. This closing marks the successful outcome of the business swap which started
with exclusive negotiations in December 2015. The complimentary report on SNY can be downloaded
at:
http://stock-callers.com/registration/?symbol=SNY
Biostar Pharma
Xianyang, the People's Republic of China headquartered Biostar Pharmaceuticals Inc.'s stock
dropped 3.62%, closing the session at $2.93. A total volume of 64,707 shares was traded. The
Company's shares have gained 4.64% on an YTD basis. The stock is trading 3.86% below its 200-day moving average. Additionally,
shares of Biostar Pharma, which develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical
products for various diseases and conditions in the People's Republic of China, have an RSI of
40.22.
On November 21st, 2016, Biostar Pharmaceuticals reported net sales of $0.6 million for Q3 2016, down 84.7% compared to Q3 2015. Sales of the Company's Shaanxi Weinan Products
decreased approximately $0.6 million, or 50.2% on a y-o-y basis during the reported quarter.
Biostar Pharmaceuticals reported net loss was $1.6 million compared to a net loss of $1.2 million for Q3 2015. Sign up for your complimentary research report on BSPM at:
http://stock-callers.com/registration/?symbol=BSPM
Heron Therapeutics
On Friday, shares in Redwood City, California headquartered Heron Therapeutics Inc. finished
the session 2.34% higher at $13.10, with a total trading volume of 685,011 shares. The stock is
trading below its 50-day moving average by 16.06%. Shares of the Company, which develops products to address unmet medical needs
using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 41.66.
On November 29th, 2016, Susan G. Komen and Heron
Therapeutics announced that the two organizations have joined forces to encourage supporters to take action in the fight against
breast cancer. Through their new partnership, Susan G. Komen and Heron Therapeutics strive to
raise awareness of the importance of supportive care in breast cancer treatment. Get free access to your research report on HRTX
at:
http://stock-callers.com/registration/?symbol=HRTX
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA